By Pushkala Aripaka and Ludwig Burger
(Reuters) - AstraZeneca's COVID-19 vaccine delivered $275 million in first-quarter sales while shaving three cents per share from earnings, the drugmaker said on Friday as it posted better-than-expected results and forecast second half growth.
This is the first time the Anglo-Swedish drugmaker has given financial details of the distribution and sales of the vaccine, which it developed with Oxford University. It has said it will not make a profit from the shot during the pandemic.
The vaccine revenue included delivery of about 68 million doses, AstraZeneca said, adding that sales in Europe, where it faces a legal case, were $224 million, in emerging markets $43 million and $8 million in the rest of the world.
Sales of $275 million for 68 million doses equates to a price tag of around $4 per shot.